![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 31, 2026
An update on our NCTN grant award, practice-changing multiple myeloma research, a promising new lung cancer study, and highlights from the Comis Translational Science Symposium
July 31, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
July 31, 2026
The latest findings in breast cancer, cardiotoxicity, leukemia, lung cancer, myeloma, NCI-MATCH, and smoking cessation support during cancer treatment
June 29, 2026
The latest findings in brain tumors, breast cancer, kidney cancer, lung cancer, Merkel cell carcinoma, and precision oncology
May 28, 2026
Dr. Anagnostou is honored as a world-renowned lung cancer translational research investigator
May 28, 2026
ACHIEVE (EA5221) is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
February 27, 2026
The latest clinical trial findings in breast cancer, leukemia, lymphoma, lung cancer, NCI-MATCH, and prostate cancer
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more